Johnson & Johnson

• JNJ Stock Price 24h change: +2.60%. From 204.47 USD to 209.79 USD. The rise was driven by strong clinical data for its cancer therapy Rybrevant (73% response rate) and a favorable court ruling reducing damages in the Auris litigation.
• Technical analysis indicates a "Strong Buy" outlook; the stock is trading above its 20, 50, and 200-day moving averages (MA200 at ~185 USD). While the RSI (62.3) and MACD suggest continued bullish momentum, short-term oscillators indicate the stock is approaching overbought territory, suggesting potential consolidation near the 215 USD resistance level.
• J&J announced it will add 500 jobs at a new manufacturing plant in North Carolina, doubling down on its 55 billion USD domestic investment plan to bolster supply chain resilience.
• A Delaware court significantly reduced the damages J&J must pay in the long-running Auris Health acquisition litigation, removing a major legal overhang and boosting investor sentiment.
• The company reached an agreement with the U.S. government to improve medicine access and lower costs for millions of Americans in exchange for manufacturing and innovation incentives.
• The 44th Annual J.P. Morgan Healthcare Conference commenced in San Francisco, with major players like Eli Lilly and Pfizer discussing AI integration in oncology and weight-loss drug expansions.
• The U.K. government launched a 600 million GBP Health Data Research Service (HDRS) led by former Moderna executive Dr. Melanie Ivarsson to accelerate life-saving drug discovery and clinical trial approvals.

• JNJ Stock Price 24h change: -0.60%. From 205.69 USD to 204.47 USD.
• From a technical perspective, JNJ exhibits a "long-term bullish, short-term neutral" stance. While the price remains above the 50-day and 200-day moving averages, it is currently testing short-term support levels near $203.25; RSI is neutral at approximately 47.6, suggesting a phase of consolidation.
• J&J recently struck a deal with the U.S. government for tariff exemptions in exchange for drug price cuts, aimed at accelerating a $55 billion U.S. manufacturing expansion.
• Barclays and Wells Fargo raised their JNJ price targets (up to $230) following clinical successes in SLE therapy and the FDA submission of the Ottava surgical robot.
• J&J announced a $1.30 quarterly dividend and provided FY2025 EPS guidance of $10.80–$10.90, reflecting steady fundamental confidence despite legal overhangs regarding talc litigation.
• The healthcare sector saw a major strike by thousands of New York City nurses over staffing and safety, impacting operations at several large hospital systems.
• The FDA issued new guidance exempting more AI-powered wearable features from medical device oversight, signaling a trend toward reduced regulatory friction for digital health tools.